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ABSTRACT
Metastatic melanoma carrying BRAF mutations represent a still unmet medical 
need as success of BRAF inhibitors is limited by development of resistance. 
Nicotinamide phosphoribosyltransferase (NAMPT) is a key enzyme in NAD 
biosynthesis. An extracellular form (eNAMPT) possesses cytokine-like functions and is 
up-regulated in inflammatory disorders, including cancer. Here we show that eNAMPT 
is actively released in culture supernatants of melanoma cell lines. Furthermore, cells 
that become resistant to BRAF inhibitors (BiR) show a significant increase of eNAMPT 
levels. Plasma from mice xenografted with BiR cell lines contain higher eNAMPT levels 
compared to tumor-free animals. Consistently, eNAMPT levels are elevated in 113 
patients with BRAF-mutated metastatic melanoma compared to 50 with localized 
disease or to 38 healthy donors, showing a direct correlation with markers of tumor 
burden, such as LDH, or aggressive disease (such as PD-L1). eNAMPT concentrations 
decrease in response to therapy with BRAF/MEK inhibitors, but increase again at 
progression, as inferred from the serial analysis of 50 patients. Lastly, high eNAMPT 
levels correlate with a significantly shorter overall survival. 
Our findings suggest that eNAMPT is a novel marker of tumor burden and 
response to therapy in patients with metastatic melanoma carrying BRAF mutations.
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INTRODUCTION
NAD is a vital molecule in all organisms and a 
major component of both energy and signal transduction 
processes [1, 2]. NAD can be synthesized from different 
routes, including a de novo pathway starting from 
tryptophan and various pathways that salvage the three 
forms of vitamin B3, namely nicotinamide, nicotinic 
acid and  nicotinamide riboside (NR). Nicotinamide, 
which is released by NAD-metabolizing enzymes, is the 
major source to maintain NAD levels, linking substrate 
and product in a functional loop [3–6]. Nicotinamide 
is recycled back to NAD via a two-step pathway 
involving nicotinamide conversion to NMN, and 
NMN adenylation to NAD. The enzyme nicotinamide 
phosphoribosyltransferase (NAMPT) catalyzes the first 
and rate-limiting reaction of the pathway [7, 8]. Beside this 
canonical intracellular activity, NAMPT was discovered 
to be present in the extracellular milieu where it exerts 
cytokine/adipokine-like actions [eNAMPT, aka pre-B 
cell colony enhancing factor (PBEF) or Visfatin] [9]. 
Elevated eNAMPT levels are typical of acute and chronic 
inflammatory conditions [8, 10], metabolic disorders 
[11–14], and cancer [15, 16]. Even if the mechanisms 
underlying eNAMPT secretion remain unknown, there 
seems to be a direct correlation with intracellular (i)
NAMPT concentration [8, 17, 18]. 
We recently studied eNAMPT functions in the 
plasma of patients with chronic lymphocytic leukemia 
(CLL), a disease where tumor-host interactions and local 
inflammation are critical in regulating disease progression. 
Our results indicate that eNAMPT levels correlate with 
disease burden and that eNAMPT creates favorable 
conditions for tumor growth, by contributing to the 
development of a population of type 2 macrophages [19]. 
The mechanisms of action of eNAMPT remain 
unclear, even if the enzymatic activity appears 
dispensable. The group of Garcia recently proposed 
that eNAMPT may bind toll-like receptor 4 (TLR4), 
activating its signaling pathway, at least in a model of 
lung endothelial cell injury [20]. Elevated eNAMPT 
levels were also described in supernatants from melanoma 
cell cultures, where both autocrine and paracrine functions 
were hypothesized [21]. 
Our recent data indicate that NAMPT becomes the 
master regulator of NAD synthesis in BRAF-mutated 
melanoma cells that acquire resistance to BRAF inhibitors 
(BRAFi) [22]. Consistently, these cells are uniquely 
sensitive to NAMPT inhibitors, both in vitro and in vivo. 
Starting from these observations, we measured 
eNAMPT levels in melanoma cell lines and in a large 
cohort of patients with BRAF-mutated metastatic 
melanomas, before and after therapy, suggesting that 
eNAMPT is a novel disease marker in BRAF-mutated 
melanoma patients.  
RESULTS
eNAMPT is present in melanoma cell line 
supernatants and in melanoma xenografts, 
increasing upon acquisition of resistance to 
BRAFi 
Recent data indicate that melanoma cells actively 
release eNAMPT in vitro [21]. By using a commercially 
available sandwich ELISA assay, we confirmed variable 
levels of eNAMPT in conditioned media from 5 BRAF-
wt and 7 BRAF-mutated (V600E) melanoma cell lines 
with no significant differences based on the presence of 
the BRAF (V600E) mutation (Figure 1A). No eNAMPT 
was found in unconditioned media added with 10% FCS 
(Figure 1A and Supplementary Figure 1A). NAMPT 
mRNA levels in these cell lines were directly correlated to 
the amount of eNAMPT (r = 0.85, P = 0.0004, Figure 1B). 
We also confirmed the presence of eNAMPT by western 
blot, analyzing conditioned media from 4 representative 
cell lines. Under reducing conditions, an anti-NAMPT-
specific antibody highlighted a single band of ≈55 kDa 
corresponding to the monomer, while under non-reducing 
conditions NAMPT dimers/multimers (100–150 kDa) 
became visible (Figure 1C), in line with previous results 
[23].
Our recent data indicate that the acquisition of BRAF 
resistance in BRAF-mutated metastatic melanoma cells 
is accompanied by a significant increase of intracellular 
NAMPT (iNAMPT), which becomes the master regulator 
of NAD biosynthesis [22]. Here we asked whether high 
iNAMPT levels in BRAF-resistant (BiR) melanoma cells 
were paralleled by elevated extracellular concentrations 
of the enzyme. To the purpose, eNAMPT levels were 
compared in the tissue culture supernatants of A375 
and M14 cells, in their sensitive (S) and BiR variants. 
eNAMPT levels in spent media from M14 cells rose from 
5 ± 0.9 to 19.7 ± 2.5 ng/ml in S vs BiR variants. In A375/S 
cells eNAMPT levels were 0.65 ± 0.08 ng/ml, increasing 
to 6.1 ± 0.5 ng/ml in BiR cells (Figure 1D). These results 
are consistent with higher NAMPT mRNA levels and 
higher intracellular levels of NAD in M14 compared to 
A375 cells (Supplementary Figure 1B). 
As a further validation of the ELISA assay, results 
were reproduced using Luminex technology, by exploiting a 
commercial assay for diabetes (Supplementary Figure 1C). 
We then dosed eNAMPT in the plasma of 
immunocompromised mice xenografted with human 
A375/BiR cell lines by subcutaneous injection. Plasma 
was collected at the baseline and after tumor masses 
reached ≈1 mm3. As the antibodies used in the ELISA 
assay cross-react with the murine protein, a mean value 
of eNAMPT in normal mouse plasma of 6.6 ng/ml was 
measured. However, engraftment of human BiR melanoma 
cells induced a significant increase of eNAMPT levels 
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(mean of 19.75 ng/ml, Figure 1E). These data are in line 
with a previous report showing that melanoma cells are 
responsible for the increase in eNAMPT levels in a mouse 
model [21]. Immunohistochemical staining performed on 
MIB1+ (i.e., proliferating) areas of the tumor confirmed 
high intracellular levels of NAMPT in live human 
xenografts in both BiR cell lines (Figure 1F). 
eNAMPT is constitutively released from 
melanoma cells
To rule out that eNAMPT in conditioned media 
was due to passive accumulation as a consequence of cell 
death, we monitored cellular viability alongside eNAMPT 
levels in BiR cell variants for 24–48–72 hours. In 
agreement with previous data [21, 23, 24], no significant 
modulation of apoptosis, as measured by annexin/
propidium iodide FACS staining, could be highlighted, 
indicanting that eNAMPT release is an active process 
(Figure 1G). Even if the mechanisms behind eNAMPT 
secretion are incompletely understood, non-classical 
pathways seem to play a role [23, 24]. In line with these 
data, brefeldin A (BfA), an inhibitor of classical secretory 
pathways, failed to significantly modulate eNAMPT levels 
(Figure 1H). 
eNAMPT is abundant in plasma from BRAF-
mutated MM patients and characterizes a set of 
patients with an unfavorable disease outcome 
The above data provide the rationale to test 
eNAMPT concentrations in the plasma of BRAF-mutated 
MM patients. Results from the analysis of 163 patients 
at different disease stages, but always untreated, indicate 
that eNAMPT levels are significantly increased in patients 
with metastatic disease (MM, n = 113, mean eNAMPT 
levels 6.5 ± 0.7 ng/ml, P < 0.0001, Supplementary 
Table 1 and Figure 2A), compared to those in stages I-II 
localized melanoma (LM, n = 50, mean eNAMPT levels 
1.9 ± 0.2 ng/ml, Figure 2A), who displayed eNAMPT 
concentrations comparable to healthy donors (HD, n = 38, 
mean eNAMPT levels 1.75 ± 0.2 ng/ml Figure 2A). Of 
note, eNAMPT levels were higher in males (n = 64, mean 
eNAMPT values 7.0 ± 1.0 ng/ml) compared to females 
(n = 49, mean eNAMPT values 5.5 ± 0.8 ng/ml). This 
difference, even if not statistically significant, was never 
highlighted in normal donors, including those examined 
for this work, and was likely due to a higher percentage 
of male patients in the M1c stage compared to females 
(70% males vs 55% females in M1c stage). In fact, when 
patients were stratified according to metastatic disease 
localization, it was apparent that patients in M1c stage 
[melanoma metastatic to any site with elevated lactate 
dehydrogenase (LDH) levels, or metastatic to visceral 
organs, excluding the lung] had significantly higher 
eNAMPT levels (mean 8.0 ± 1.1 ng/ml) than patients in 
M1a stage [skin or lymph node metastases with normal 
LDH, (mean 3.5  ±  0.7 ng/ml, P = 0.009)], while patients 
in M1b stage (metastasis to the lungs with normal LDH) 
showed intermediate values (mean 5.5 ± 1.1 ng/ml, Figure 
2B). Consistently, a direct correlation between eNAMPT 
and LDH levels was highlighted in 39 patients for whom 
LDH measurement had been performed on the same 
sample used for eNAMPT testing (r = 0.41, P = 0.008, 
Figure 2C), in keeping with the notion that eNAMPT 
plasma levels correlate with tumor burden. 
Moreover, for 26 patients we had data on the 
immunohistochemical expression of PD-L1, which is 
considered a negative prognostic marker [25]. Out of 
them, the 8 patients with a PD-L1+ lesion had significantly 
higher eNAMPT levels compared to negative ones (Figure 
2D), suggesting a correlation between eNAMPT and an 
immunosuppressed microenvironment.
eNAMPT enzymatic activity in sera from 5 MM 
patients with variable eNAMPT levels was then measured 
using an ad hoc devised assay [26]. Both substrates 
[nicotinamide and phosphoribosyl pyrophosphate 
(PRPP)], as well as ATP, which is known to increase the 
catalytic efficiency of the enzyme [27], were added to the 
reaction mixtures. Under these conditions, 4/5 sera showed 
formation of nicotinamide mononucleotide (NMN), the 
product of the NAMPT-catalyzed reaction (mean activity 
of 3.7 ± 0.9 nmol NMN/ml). Interestingly, the plasma 
where NAMPT activity could not be measured was the 
one with the lowest eNAMPT levels (Figure 2E). 
Follow up data were available for 62 MM patients. 
By applying recursive partitioning analysis to this cohort 
an eNAMPT cut-off of 12.72 ng/ml was determined. 
The 16 patients with eNAMPT levels >12.72 ng/ml 
showed inferior overall survival (OS, median 9 months), 
compared to the 46 patients with eNAMPT levels ≤12.72 
ng/ml (median 29 months; log-rank test P = 0.009, Figure 
2F). All patients (16/16) with high levels of eNAMPT 
experienced disease progression, at variance with those 
with low levels of eNAMPT where progression occurred 
only in 11/46 (24%).
eNAMPT levels decrease in response to therapy, 
increasing again upon disease progression
Plasmatic NAMPT levels were then prospectically 
followed at different time points in a cohort of 62 stage 
IV melanoma patients treated with BRAFi alone or in 
combination with MEK inhibitors (MEKi). A sample from 
each patient was obtained at the baseline, after 4 weeks of 
therapy and at a third time point varying between 2 and 6 
months. We excluded from this analysis patients for whom 
eNAMPT levels fell within the normal range, by applying 
a cut-off of ≥1.75 ng/ml. In the remaining 50 patients, 
a significant drop in eNAMPT levels was observed at 
the first time point in the analysis, where all patients 
experienced some level of response to therapy (mean 
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Figure 1: Melanoma cells release high eNAMPT levels. (A) eNAMPT concentrations (ng/ml) measured with a quantitative 
ELISA assay in the supernatant (SN) of 5 BRAF-wt and 7 BRAF-mutated melanoma cell lines. Medium corresponds to RPMI 10% FCS. 
(B) Regression line showing a positive correlation between NAMPT mRNA levels (x-axis) and eNAMPT (y-axis) detected in the same 12 
melanoma cell lines. Pearson coefficient (r) and the corresponding P value are noted. (C) The presence of eNAMPT was confirmed by 
western blot performed on 10× concentrated culture supernatants from WKMEL, 1061-MEL, M14 and A375 cell lines in reducing and 
not-reducing conditions. Rec (recombinant NAMPT) was loaded as control. (D–E) ELISA assay showing eNAMPT concentrations in SN 
from M14/S and /BiR (n = 10) and A375/S and /BiR (n = 10) (D) or in plasma from NSG mice xenografted by subcutaneous injection of 
A375/BiR cell lines (n = 8). Bas: eNAMPT levels in plasma collected before tumor xenotransplantation, A375/BiR: eNAMPT levels in 
plasma collected after tumor masses reached 1 mm3 (E). (F) Representative images of MIB1/NAMPT staining in tumor sections derived 
from NSG mice xenografted with BiR cells. Original magnification 20×. Scale bar  =  100 μm. (G) Graphs showing eNAMPT values in the 
SN of M14/BiR and A375/BiR measured at 24, 48 and 72 hours (black left y axis, n = 3) and concomitant % of apoptotic cells (AnnexinV+/
propidium iodide+) in the same cells for the time indicated (red right y axis, n = 3). (H) ELISA assay showing eNAMPT concentrations in 
SN from M14/BiR and A375/BiR cells treated with 1µg/ml of BfA for 6 hours (n = 3).
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eNAMPT levels pre-therapy [T = 0] 8.4 ± 0.9 ng/ml, mean 
eNAMPT after 1 month [T = 1] of therapy 4 ± 0.5 ng/
ml, P < 0.0001, Figure 2G). eNAMPT levels were then 
analyzed at a later time point (varying from 2–6 months 
after beginning of therapy), where patients had either 
consolidated the clinical response or were experiencing 
progression. In the patients that consolidated the response 
(T = R, n =  28), eNAMPT was further decreased (mean 
3.2 ± 0.5 ng/ml, P = 0.0001, Figure 2G), while it increased 
in the 19/22 patients with disease progression (T = P, mean 
11.1 ± 2.2 ng/ml, P =  0.0003, Figure 2G). 
DISCUSSION
This work focuses on the analysis of eNAMPT 
levels in patients with BRAF-mutated melanoma. NAMPT 
is an intracellular enzyme that controls a critical step in 
one of the pathways leading to NAD biosynthesis. It has 
long been known that NAMPT is present in extracellular 
fluids, where it was originally described as a cytokine-
like molecule, which promoted growth and differentiation 
of B cell precursors [9]. We now know that eNAMPT is 
elevated in conditions of chronic inflammation, including 
cancer [8, 16], where it is likely to contribute to local 
immunosuppression [19].
The choice of melanoma derives from our recent 
study, which indicates that NAMPT becomes the dominant 
NAD-biosynthetic enzyme in BRAF-resistant melanoma 
cell lines and patients BRAF-mutated [22]. Here we 
show that melanoma cells can release eNAMPT, most 
likely through a non-classical secretory pathway, and 
independently of their BRAF mutational status, suggesting 
that these cells are intrinsically able to secrete this enzyme. 
Accordingly, eNAMPT is found in the plasma of mice 
xenografted with human melanoma cells. An important 
finding is that spent media from BRAF-mutated cells that 
were rendered resistant to BRAFi and that overexpress 
iNAMPT, contain significantly higher eNAMPT levels 
compared to the sensitive counterparts, suggesting that 
the extracellular version of the molecule is proportional to 
the intracellular one. 
We then evaluated eNAMPT in 163 patients with 
BRAF-mutated melanoma. The first indication here 
is that eNAMPT levels increase substantially when 
the disease becomes metastatic, while patients with a 
localized disease were undistinguishable from healthy 
controls. Second, the amount of eNAMPT shows a direct 
correlation with LDH, which is considered a marker 
of tumor burden. Third, the highest levels of eNAMPT 
are typical of patients with visceral metastases (M1c), 
compared to patients in the M1a stage. A subgroup of 62 
of these patients was treated with BRAFi or MEKi, with 
follow-up data available for analysis. The first observation 
is that patients with eNAMPT levels above the threshold 
of 12.72 ng/ml, defined based on a recursive partitioning 
analysis, died significantly earlier compared to patients 
with lower eNAMPT levels. Importantly, 16/16 of patients 
with >12.72 ng/ml of eNAMPT experienced disease 
progression, at variance with only 11/46 in the subgroup 
with lower eNAMPT levels. Furthermore, eNAMPT levels 
in treated patients could be followed during the course of 
therapy. Results show that 1 month after beginning therapy 
with BRAFi/MEKi, when most patients were responding, 
eNAMPT levels dropped significantly, but picked up again 
specifically in patients who relapsed. On the contrary, 
they decreased further over the course of 2–6 months in 
patients that consolidated responses to targeted therapies.
Overall, these data suggest that eNAMPT should be 
further studied as a disease marker for melanoma patients 
with a BRAF-mutated tumor. From the functional stand 
point, eNAMPT may exert more complex functions 
in the melanoma microenvironment than being a mere 
reflection of the intracellular levels of the enzyme. Grolla 
et al. recently demonstrated that eNAMPT released by 
melanoma cell line in vitro had paracrine and autocrine 
effects activating nuclear factor kappa B (NF-KB) 
signaling and increasing colony-formation in anchorage-
independent conditions [21]. On the other side, nothing 
is known yet on the effects of eNAMPT in the tumor 
microenvironment. However, it is of interest to note that 
both melanoma cells and tumor-infiltrating macrophages 
can express TLR4 [28–30], which was recently identified 
as the eNAMPT receptor [20]. A tumor-supportive, 
immune-suppressive function for eNAMPT was shown 
in chronic lymphocytic leukemia [19] and in other tumor 
models [8]. It is however also possible that the biological 
actions of eNAMPT also depend on its enzymatic 
activity. Our data indicate that the extracellular version 
of the molecule is enzymatically active, provided that the 
substrates are available. If so, eNAMPT could also lead 
to the modulation of extracellular NAD concentrations, 
likely affecting purinergic receptor signaling [31].
In conclusion, this work shows that eNAMPT levels 
increase during melanoma progression and upon BRAFi 
resistance development, negatively correlating with patient 
overall survival. Further studies are needed to confirm that 
eNAMPT is a marker of disease burden and possibly an 
independent negative prognostic factor in BRAF-mutated 
MM patients, as well as a critical element in the induction 
of immunosuppressive and tumor-promoting conditions in 
the melanoma microenvironment. 
MATERIALS AND METHODS 
Patients
All patients enrolled in the study provided written 
informed consent. BRAF (V600E) mutational status was 
determined by Sanger sequencing. Patient plasma or sera 
were collected in accordance with the Institutional Review 
Board and the Declaration of Helsinki. All patients 
received BRAFi alone (Dabrafenib or Vemurafenib) 
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or a combination of BRAFi and MEKi (Trametinib). 
Clinical features of the metastatic patients are indicated in 
Supplementary Table 1. For some patients information on 
the levels of LDH (UI/mL) or PD-L1 expression on tissue 
biopsies [32] were available.
Blood samples from healthy donors were obtained 
through the local blood bank.
Cell lines
BRAF WT cell lines were: SK-MEL-2, 501-
MEL, 4778D-MEL WKMEL and 197-MEL. BRAF-
mutated (V600E) cell lines were: A375, M14, SK-
MEL-5, COLO38, FO-1, 1061-MEL, MEL-MAI. BRAF 
mutational status (V600E) was confirmed by Sanger 
Figure 2: eNAMPT levels are significantly increased in patients with MM and correlate with response to therapy and 
overall survival. (A) eNAMPT levels measured using an ELISA assay in sera from healthy donors (HD, n = 38), patients with a localized 
melanoma (LM, n = 50) or patients with metastatic disease (MM, n = 113). (B) ELISA assay showing eNAMPT concentrations in sera 
of stage IV melanoma patients subdivided in M1a, M1b and M1c subcategories. The horizontal line in (A–B) around 2 ng/ml indicated 
mean eNAMPT level in HD subjects. (C) Regression line showing a positive correlation between LDH (x-axis) and eNAMPT (y-axis) 
levels detected in 39 sera from MM patients. Pearson coefficient (r) and the corresponding P value are noted. (D) ELISA assay showing 
eNAMPT concentrations in sera from MM patients with PD-L1+ (n = 8) or PD-L1- (n = 18) lesion (cut-off level >5% or <5% respectively). 
(E) eNAMPT activity determined in sera from 5 MM patients, with variable eNAMPT levels (indicated in brackets as ng/ml for each 
MM serum), as described in the Methods section. (F) Kaplan–Meyer curves showing overall survival (OS) of a cohort of 62 MM patients 
divided on the basis of eNAMPT levels (cut-off 12.72 ng/ml) at diagnosis. Log-rank test showed statistical significance. (G) ELISA assay 
showing eNAMPT concentrations in sera from 50 MM patients before and after therapy with a BRAFi alone or in combination with MEKi 
(T = 0). Graph on the left shows eNAMPT values before therapy and after 1 month of treatment (T = 1), where all patients showed some 
degree of response. The central panels shows eNAMPT levels in sera from 28 responsive MM patients at T = 1 (1 month of therapy) and 
at T = R (2–6 months later with consolidation of the clinical response). The graph on the right shows values in 22 progressive MM patients 
at T = 1 (1 month of therapy) and at T = P (at time of progression 6 months. The horizontal line, in all graphs indicates the mean eNAMPT 
level in HD subjects.
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sequencing. A375 and M14 BRAF-resistant (BiR) cells 
were generated by adding increasing concentrations of the 
BRAF inhibitor (BRAFi) Dabrafenib (GlaxoSmithKline) 
to complete medium, reaching the final concentration of 
1.6 µM in ≈10 weeks. BiR cells were then maintained 
under these conditions. Culture conditions are described 
in Supplementary Material and Methods (SMM). 
Xenograft models
A375 and M14 BiR melanoma cells (5 × 106) 
were resuspended in Matrigel® (Corning) and injected 
into the right and left flank of 6–8-week old male NOD/
SCID/gamma chain-/-(NSG) mice (Charles River). Once 
tumors became palpable mice were sacrificed and tumors 
processed. Plasma samples were obtained at the baseline 
and at sacrifice for A375 BiR engraftments.
Assays to quantify eNAMPT in biological fluids
eNAMPT concentrations in plasma and culture 
supernatants were determined using human NAMPT 
Enzyme-Linked Immunosorbent Assay (ELISA) kit 
(Adipogen). To validate results, some samples were 
analyzed also through Luminex Technology using Bio-
Plex Pro Human Diabetes Assay panel (Bio-Rad) that 
includes NAMPT. 
Preparation of culture supernatants and Western 
blot 
For eNAMPT measurement melanoma cells 
(1.5x105) were seeded in 24-well plates in media plus 
0.1%FCS (Sigma) for 24 hours. Spent media was then 
collected and concentrated 10x using 30 kDa cut off filters 
(Amicon Ultra centrifugal Filters, Millipore) and  then 
analyzed by western blot as described in SMM.
Treatments with Brefeldin A
M14 and A375 BiR (2.5 × 105) were seeded in 24-
well plates in complete medium and treated or not with 
Brefeldin A (BfA, 1 µg/ml, Sigma) for 6 hours before 
collecting supernatants and performing the ELISA 
assay. 
NAMPT activity in plasma
NAMPT activity was determined by a multicoupled 
fluorometric assay, developed to measure NAMPT activity 
in cell crude extracts and biological fluids [26].
RNA extraction and quantitative real-time 
polymerase chain reaction (qRT-PCR)
RNA was extracted and RT-PCR performed as 
described in SMM. 
Cell viability 
Cell viability was measured using the Annexin-V-
FITC Apoptosis Kit (Valter Occhiena). Data were acquired 
using a FACSCanto II cytofluorimeter and processed with 
DIVA version 8 (BD Biosciences). 
Immunohistochemistry
Formalin-fixed, paraffin-embedded skin sections 
were stained as described in SMM. Images were acquired 
using a CANON EOS 600D camera fitted to AXIO Lab 
A1 Zeiss microscope.
Statistical analyses
Mann–Whitney U (unpaired data), or Wilcoxon 
signed rank (paired data) tests were used to compare 
continuous variables. Overall survival (OS) was calculated 
as the time from melanoma diagnosis to death. Patients 
who neither recurred nor died at the end of the study 
were censored at the time of the last follow-up. Survival 
curves were estimated with the Kaplan-Meier method 
and compared by means of Log-rank test. Recursive 
partitioning analysis (RPA) was applied to define the 
best eNAMPT cut-off in our series. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, ****P ≤ 0.0001.
Statistical analyses were performed with GraphPad 
version 6.0, SAS version 9.4 and R version 3.2.5 
softwares.
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